Journal
NANOMEDICINE
Volume 9, Issue 11, Pages 1665-1679Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/NNM.13.123
Keywords
acute myeloid leukemia; C2-ceramide; hemolysis; liposome; safingol; sever combined immunodeficiency mouse; sphingolipid; synergistic combination; U937; zeta-potential
Funding
- Singapore's Ministry of Education through the National University of Singapore Academic Research Fund FRC-Tier 1 grant [R-148-000-098-112]
- National University of Singapore graduate research scholarship
Ask authors/readers for more resources
Aim: The aim of this work was to develop a liposomal formulation to facilitate delivery of a synergistic safingol/C2-ceramide combination in the treatment of acute myeloid leukemia (AML). Materials & methods: Liposomes were prepared using the extrusion method and the bioactive lipids were encapsulated passively. Drug concentrations were determined by liquid chromatography tandem mass spectrometry. Antileukemic activity was evaluated using human leukemic cell lines, patient samples and U937 leukemic xenograft models. Results: A stable liposome formulation was developed to coencapsulate safingol and C2-ceramide at 1: 1 molar ratio with >90% encapsulation efficiency. The liposomal safingol/C2-ceramide was effective in AML cell lines, patient samples and murine xenograft models of AML, compared with liposomal safingol or liposomal C2-ceramide alone despite a dose reduction of 33%. Conclusion: Our study provided proof-of-concept evidence to deliver synergistic combination of bioactive lipid to achieve complete remission in AML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available